Idgliptin 20mg Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin enhances glycemic control by prolonging the activity of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving postprandial and fasting blood glucose levels. This medication is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled by lifestyle modifications alone or in combination with other antidiabetic agents. Idgliptin exhibits a favorable pharmacokinetic profile with a long half-life, allowing once-daily dosing, which may improve patient adherence. It is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. Common adverse effects may include nasopharyngitis, headache, and gastrointestinal disturbances, though serious side effects are rare. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy. Idgliptin should be used under medical supervision, with attention to potential drug interactions and contraindications.